Gelonghui, Feb. 1 | Kaituo Pharmaceutical-B (09939.HK) announced that its self-developed and potentially pioneering phase IB/III clinical trial of KX-826 combined with minoxidil to treat male androgenic alopecia (“AGA”) in Chinese adult male androgenic alopecia (“AGA”) has recently been approved by the National Drug Administration (“NMPA”) to evaluate the efficacy and safety of KX-826 combined with minoxidil in the treatment of male adult AGA patients in China.
KX-826 is one of the Group's core drugs. Since its development, it has completed multiple clinical trials for men and women for hair loss treatment in China and the United States, and has shown excellent safety and efficacy trends. Minoxidil is one of the mainstream approved drugs for AGA. It was approved by the US Food and Drug Administration (“FDA”) in 1988 to treat hair loss. The Group believes that through the exploration of combination therapies, the therapeutic effects of KX-826 in the field of hair loss will be further explored. At the same time, the Group is carrying out and planning to launch multiple clinical trials of KX-826 to treat hair loss and acne, and continue to develop the value of KX-826 for use in the dermatological field.